<?xml version="1.0" ?>
<text author="Guilaine Boursier, Cécile Rittore, Sophie Georgin-Lavialle, Alexandre Belot, Caroline Galeotti, Eric Hachulla, Véronique Hentgen, Linda Rossi-Semerano, Guillaume Sarrabay, and Isabelle Touitou" dateCollected="2019-11-03" id="amalgum_academic_doc648" shortTile="positive-impact-expert" sourceURL="https://www.mdpi.com/2077-0383/8/10/1729/htm" speakerCount="0" speakerList="none" title="Positive Impact of Expert Reference Center Validation on Performance of Next-Generation Sequencing for Genetic Diagnosis of Autoinflammatory Diseases" type="academic">
<head>
<s type="frag">
4.	LS	@ord@
Discussion	NN	discussion
</s>
</head>
<p>
<s type="ger">
Recognizing	VBG	recognize
patients	NNS	patient
with	IN	with
monogenic	NN	monogenic
</s>
<s type="decl">
AIDs	NN	aId
is	VBZ	be
difficult	JJ	difficult
because	IN	because
their	PRP$	their
clinical	JJ	clinical
spectrum	NN	spectrum
may	MD	may
range	VB	range
from	IN	from
very	RB	very
mild	JJ	mild
inflammatory	JJ	inflammatory
episodes	NNS	episode
to	TO	to
severe	JJ	severe
chronic	JJ	chronic
disease	NN	disease
.	.	.
</s>
<s type="decl">
Moreover	RB	moreover
,	,	,
the	DT	the
disease	NN	disease
features	VBZ	feature
significantly	RB	significantly
overlap	VBP	overlap
.	.	.
</s>
<s type="decl">
Our	PRP$	our
targeted	JJ	target
NGS	NNP	NGS
approach	NN	approach
resulted	VBD	result
in	IN	in
genetic	JJ	genetic
confirmation	NN	confirmation
in	IN	in
a	DT	a
relatively	RB	relatively
small	JJ	small
proportion	NN	proportion
(	-LRB-	(
7	CD	7
%	NN	%
)	-RRB-	)
of	IN	of
patients	NNS	patient
.	.	.
</s>
<s type="decl">
This	DT	this
finding	NN	finding
is	VBZ	be
consistent	JJ	consistent
with	IN	with
two	CD	two
2019	CD	@card@
reports	NNS	report
by	IN	by
Karacan	NNP	Karacan
et	FW	et
al.	FW	al.
and	CC	and
Papa	NNP	Papa
et	FW	et
al.	FW	al.
,	,	,
who	WP	who
used	VBD	use
recent	JJ	recent
guidelines	NNS	guideline
for	IN	for
the	DT	the
definition	NN	definition
of	IN	of
positive	JJ	positive
diagnosis	NN	diagnosis
as	IN	as
we	PRP	we
did	VBD	do
.	.	.
</s>
<s type="decl">
Three	CD	Three
previous	JJ	previous
studies	NNS	study
using	VBG	use
a	DT	a
broader	JJR	broad
definition	NN	definition
claimed	VBD	claim
19	CD	@card@
%	NN	%
,	,	,
20	CD	@card@
%	NN	%
,	,	,
and	CC	and
22	CD	@card@
%	NN	%
diagnostic	JJ	diagnostic
yield	NN	yield
.	.	.
</s>
<s type="decl">
In	IN	in
those	DT	those
reports	NNS	report
,	,	,
for	IN	for
example	NN	example
,	,	,
frequent	JJ	frequent
variants	NNS	variant
,	,	,
such	JJ	such
as	IN	as
p.	NNP	P.
(	-LRB-	(
Glu148Gln	NNP	Glu148Gln
)	-RRB-	)
(	-LRB-	(
<hi rend="italic">
MEFV	NNP	MEFV
</hi>
)	-RRB-	)
,	,	,
p.	NN	P.
(	-LRB-	(
Arg121Gln	NNP	Arg121Gln
)	-RRB-	)
(	-LRB-	(
<hi rend="italic">
TNFRSF1A	NNP	TNFRSF1A
</hi>
)	-RRB-	)
,	,	,
or	CC	or
p.	NNP	P.
(	-LRB-	(
Val198Met	NNP	Val198Met
)	-RRB-	)
(	-LRB-	(
<hi rend="italic">
NLRP3	NNP	NLRP3
</hi>
)	-RRB-	)
,	,	,
and	CC	and
all	DT	all
known	VBN	know
susceptibility	NN	susceptibility
factors	NNS	factor
for	IN	for
inflammation	NN	inflammation
were	VBD	be
considered	VBN	consider
consistent	JJ	consistent
with	IN	with
the	DT	the
diagnosis	NN	diagnosis
.	.	.
</s>
<s type="decl">
Moreover	RB	moreover
,	,	,
our	PRP$	our
definition	NN	definition
was	VBD	be
more	RBR	more
stringent	VBG	stringent
than	IN	than
these	DT	these
four	CD	four
previous	JJ	previous
studies	NNS	study
because	IN	because
we	PRP	we
considered	VBD	consider
that	IN	that
we	PRP	we
could	MD	could
not	RB	not
conclude	VB	conclude
on	IN	on
the	DT	the
diagnosis	NN	diagnosis
when	WRB	when
the	DT	the
parent	NN	parent
’s	POS	&apos;s
DNA	NNP	NN
was	VBD	be
lacking	VBG	lack
segregation	NN	segregation
analyses	NNS	analysis
of	IN	of
heterozygous	JJ	heterozygous
rare	JJ	rare
VOUS	NNP	VoUS
.	.	.
</s>
</p>
<p>
<s type="sub">
The	DT	the
low	JJ	low
performance	NN	performance
of	IN	of
the	DT	the
AIDs	NNP	aId
panel	NN	panel
might	MD	might
also	RB	also
be	VB	be
explained	VBN	explain
by	IN	by
our	PRP$	our
study	NN	study
design	NN	design
that	WDT	that
did	VBD	do
not	RB	not
include	VB	include
most	JJS	most
of	IN	of
the	DT	the
patients	NNS	patient
with	IN	with
features	NNS	feature
of	IN	of
FMF	NNP	FMF
,	,	,
MKD	NNP	MKD
,	,	,
and	CC	and
DADA2	NNP	DADA2
because	IN	because
they	PRP	they
were	VBD	be
screened	VBN	screen
by	IN	by
Sanger	NNP	Sanger
sequencing	NN	sequence
.	.	.
</s>
<s type="decl">
Still	RB	still
,	,	,
the	DT	the
genes	NNS	gene
<hi rend="italic">
MEFV	NNP	MEFV
</hi>
,	,	,
<hi rend="italic">
MVK	NNP	MVK
,	,	,
</hi>
and	CC	and
<hi rend="italic">
ADA2	NNP	ADA2
</hi>
remained	VBD	remain
among	IN	among
the	DT	the
four	CD	four
most	RBS	most
frequently	RB	frequently
involved	VBN	involve
in	IN	in
the	DT	the
conclusive	JJ	conclusive
diagnoses	NNS	diagnose
of	IN	of
our	PRP$	our
study	NN	study
.	.	.
</s>
<s type="decl">
This	DT	this
observation	NN	observation
possibly	RB	possibly
stems	VBZ	stem
from	IN	from
a	DT	a
better	JJR	good
detection	NN	detection
by	IN	by
NGS	NNP	NGS
of	IN	of
the	DT	the
new	JJ	new
molecular	JJ	molecular
mechanisms	NNS	mechanism
involved	VBN	involve
in	IN	in
AIDs	NNP	aId
(	-LRB-	(
mosaicism	NN	mosaicism
,	,	,
CNVs	NNS	CNV
)	-RRB-	)
and	CC	and
better	JJR	good
information	NN	information
on	IN	on
these	DT	these
three	CD	three
diseases	NNS	disease
because	IN	because
they	PRP	they
are	VBP	be
among	IN	among
the	DT	the
best-described	JJ	best-described
AIDs	NNP	aId
.	.	.
</s>
<s type="decl">
In	IN	in
addition	NN	addition
,	,	,
FMF	NNP	FMF
is	VBZ	be
now	RB	now
recognized	VBN	recognize
as	IN	as
a	DT	a
disease	NN	disease
caused	VBN	cause
by	IN	by
gain-of-function	JJ	gain-of-function
variants	NNS	variant
with	IN	with
a	DT	a
dosage	NN	dosage
effect	NN	effect
rather	RB	rather
than	IN	than
a	DT	a
purely	RB	purely
recessive	JJ	recessive
condition	NN	condition
.	.	.
</s>
<s type="decl">
For	IN	for
one-third	NN	one-third
of	IN	of
the	DT	the
patients	NNS	patient
with	IN	with
one	CD	one
heterozygous	JJ	heterozygous
pathogenic	JJ	pathogenic
variant	NN	variant
in	IN	in
a	DT	a
recessive	JJ	recessive
condition	NN	condition
,	,	,
the	DT	the
gene	NN	gene
was	VBD	be
<hi rend="italic">
MEFV	NNP	MEFV
</hi>
.	.	.
</s>
<s type="sub">
If	IN	if
we	PRP	we
had	VBD	have
included	VBN	include
heterozygous	JJ	heterozygous
carriers	NNS	carrier
of	IN	of
a	DT	a
<hi rend="italic">
MEFV	JJ	MEFV
</hi>
pathogenic	JJ	pathogenic
variant	NN	variant
,	,	,
the	DT	the
genetic	JJ	genetic
diagnosis	NN	diagnosis
yield	NN	yield
would	MD	would
have	VB	have
improved	VBN	improve
up	RP	up
to	TO	to
10	CD	@card@
%	NN	%
(	-LRB-	(
</s>
<figure>
<s type="frag">
Figure	NN	Figure
2	CD	2
</s>
</figure>
<s type="frag">
)	-RRB-	)
.	.	.
</s>
</p>
<p>
<s type="decl">
In	IN	in
an	DT	an
attempt	NN	attempt
to	TO	to
find	VB	find
a	DT	a
cause	NN	cause
that	WDT	that
could	MD	could
explain	VB	explain
the	DT	the
low	JJ	low
rate	NN	rate
of	IN	of
genetic	JJ	genetic
confirmation	NN	confirmation
using	VBG	use
panels	NNS	panel
in	IN	in
the	DT	the
patients	NNS	patient
referred	VBN	refer
to	TO	to
us	PRP	us
,	,	,
we	PRP	we
wondered	VBD	wonder
whether	IN	whether
validation	NN	validation
of	IN	of
the	DT	the
request	NN	request
by	IN	by
a	DT	a
specialized	JJ	specialize
reference	NN	reference
center	NN	center
could	MD	could
improve	VB	improve
this	DT	this
performance	NN	performance
.	.	.
</s>
<s type="decl">
The	DT	the
success	NN	success
of	IN	of
the	DT	the
NGS	NNP	NGS
approach	NN	approach
was	VBD	be
suggested	VBN	suggest
to	TO	to
rely	VB	rely
on	IN	on
its	PRP$	its
use	NN	use
in	IN	in
the	DT	the
context	NN	context
of	IN	of
a	DT	a
highly	RB	highly
specialized	VBN	specialize
clinical	JJ	clinical
service	NN	service
for	IN	for
patients	NNS	patient
with	IN	with
AIDs	NNP	aId
.	.	.
</s>
<s type="decl">
National	JJ	national
reference	NN	reference
centers	NNS	center
and	CC	and
networks	NNS	network
cover	VBP	cover
all	PDT	all
the	DT	the
expertise	NN	expertise
necessary	JJ	necessary
for	IN	for
patient	NN	patient
care	NN	care
and	CC	and
operational	JJ	operational
management	NN	management
and	CC	and
efficiency	NN	efficiency
.	.	.
</s>
<s type="decl">
We	PRP	we
established	VBD	establish
a	DT	a
pre-requisite	NN	pre-requisite
for	IN	for
a	DT	a
systematic	JJ	systematic
evaluation	NN	evaluation
of	IN	of
undifferentiated	VBN	undifferentiated
AIDs	NN	aId
patients	NNS	patient
by	IN	by
clinicians	NNS	clinician
from	IN	from
reference	NN	reference
centers	NNS	center
.	.	.
</s>
<s type="decl">
It	PRP	it
is	VBZ	be
possible	JJ	possible
that	IN	that
many	JJ	many
doctors	NNS	doctor
from	IN	from
non-reference	JJ	non-reference
centers	NNS	center
could	MD	could
not	RB	not
find	VB	find
the	DT	the
time	NN	time
to	TO	to
present	VB	present
their	PRP$	their
patients	NNS	patient
to	TO	to
MSM	NNP	MSM
.	.	.
</s>
<s type="frag">
This	DT	this
certainly	RB	certainly
accounts	VBZ	account
for	IN	for
the	DT	the
decrease	NN	decrease
in	IN	in
the	DT	the
proportion	NN	proportion
of	IN	of
patients	NNS	patient
referred	VBN	refer
by	IN	by
the	DT	the
non-reference	JJ	non-reference
centers	NNS	center
.	.	.
</s>
<s type="decl">
However	RB	however
,	,	,
our	PRP$	our
study	NN	study
showed	VBD	show
that	IN	that
this	DT	this
strategy	NN	strategy
resulted	VBD	result
in	IN	in
a	DT	a
better	JJR	good
clinical	JJ	clinical
filter	NN	filter
for	IN	for
ordering	VBG	order
genetic	JJ	genetic
tests	NNS	test
and	CC	and
almost	RB	almost
doubled	VBD	doubled
the	DT	the
performance	NN	performance
of	IN	of
our	PRP$	our
NGS	NNP	NGS
strategy	NN	strategy
.	.	.
</s>
<s type="decl">
Also	RB	also
,	,	,
our	PRP$	our
reference	NN	reference
center	NN	center
recently	RB	recently
offered	VBD	offer
a	DT	a
diagnostic	JJ	diagnostic
checklist	NN	checklist
to	TO	to
guide	VB	guide
practitioners	NNS	practitioner
who	WP	who
may	MD	may
suspect	VB	suspect
an	DT	an
AID	NN	AID
for	IN	for
ordering	VBG	order
genetic	JJ	genetic
tests	NNS	test
.	.	.
</s>
<s type="decl">
In	IN	in
our	PRP$	our
patients	NNS	patient
with	IN	with
a	DT	a
conclusive	JJ	conclusive
diagnosis	NN	diagnosis
of	IN	of
AID	NNP	AID
,	,	,
the	DT	the
main	JJ	main
features	NNS	feature
identified	VBD	identify
were	VBD	be
mucocutaneous	JJ	mucocutaneous
,	,	,
articular	JJ	articular
,	,	,
and	CC	and
gastro-intestinal	NN	gastro-intestinal
.	.	.
</s>
<s type="decl">
This	DT	this
result	NN	result
reflects	VBZ	reflect
daily	JJ	daily
practice	NN	practice
because	IN	because
the	DT	the
cutaneous/mucosal	NN	cutaneous/mucosal
,	,	,
digestive	JJ	digestive
tract	NN	tract
,	,	,
and	CC	and
musculoskeletal	JJ	musculoskeletal
systems	NNS	system
are	VBP	be
the	DT	the
three	CD	three
most	RBS	most
common	JJ	common
systems	NNS	system
involved	VBN	involve
in	IN	in
AIDs	NNP	aId
.	.	.
</s>
</p>
<p>
<s type="decl">
We	PRP	we
cannot	MD	can
rule	VB	rule
out	RP	out
a	DT	a
relative	JJ	relative
underestimation	NN	underestimation
of	IN	of
the	DT	the
potential	NN	potential
of	IN	of
NGS	NNP	NGS
panels	NNS	panel
for	IN	for
AIDs	NNP	aId
in	IN	in
general	NN	general
.	.	.
</s>
<s type="decl">
Indeed	RB	indeed
,	,	,
because	IN	because
of	IN	of
our	PRP$	our
study	NN	study
design	NN	design
,	,	,
some	DT	some
of	IN	of
the	DT	the
patients	NNS	patient
or	CC	or
their	PRP$	their
relatives	NNS	relative
were	VBD	be
not	RB	not
available	JJ	available
for	IN	for
NGS	NNP	NGS
or	CC	or
segregation	NN	segregation
analysis	NN	analysis
.	.	.
</s>
<s type="decl">
However	RB	however
,	,	,
our	PRP$	our
aim	NN	aim
was	VBD	be
not	RB	not
to	TO	to
evaluate	VB	evaluate
the	DT	the
exact	JJ	exact
performance	NN	performance
of	IN	of
NGS	NNP	NGS
but	CC	but
to	TO	to
find	VB	find
ways	NNS	way
to	TO	to
improve	VB	improve
it	PRP	it
.	.	.
</s>
<s type="decl">
In	IN	in
addition	NN	addition
to	TO	to
the	DT	the
successful	JJ	successful
clinical	JJ	clinical
option	NN	option
we	PRP	we
demonstrated	VBD	demonstrate
here	RB	here
,	,	,
it	PRP	it
is	VBZ	be
easy	JJ	easy
to	TO	to
predict	VB	predict
the	DT	the
upcoming	JJ	upcoming
discovery	NN	discovery
of	IN	of
new	JJ	new
genes	NNS	gene
or	CC	or
molecular	JJ	molecular
mechanisms	NNS	mechanism
involved	VBN	involve
in	IN	in
AIDs	NNP	aId
that	WDT	that
will	MD	will
continue	VB	continue
to	TO	to
revolutionize	VB	revolutionize
our	PRP$	our
routine	NN	routine
genetic	JJ	genetic
diagnosis	NN	diagnosis
.	.	.
</s>
<s type="decl">
Recent	JJ	Recent
inputs	NNS	input
of	IN	of
the	DT	the
literature	NN	literature
advocate	VBP	advocate
closer	JJR	close
interactions	NNS	interaction
between	IN	between
clinicians	NNS	clinician
and	CC	and
geneticists	NNS	geneticist
in	IN	in
the	DT	the
era	NN	era
of	IN	of
whole-genome	JJ	whole-genome
sequencing	NN	sequence
.	.	.
</s>
<s type="decl">
Among	IN	Among
them	PRP	them
are	VBP	be
the	DT	the
identification	NN	identification
of	IN	of
genetic	JJ	genetic
modifiers	NNS	modify
,	,	,
affecting	VBG	affect
the	DT	the
penetrance	NN	penetrance
of	IN	of
homozygous	NN	homozygous
pathogenic	NN	pathogenic
<hi rend="italic">
MVK	NNP	MVK
</hi>
:	:	:
p.	NNP	P.
(	-LRB-	(
Val377Ile	NNP	Val377Ile
)	-RRB-	)
variant	NN	variant
;	:	;
the	DT	the
lack	NN	lack
of	IN	of
detection	NN	detection
of	IN	of
pathogenic	JJ	pathogenic
variants	NNS	variant
in	IN	in
patients	NNS	patient
with	IN	with
a	DT	a
clear	JJ	clear
given	VBN	give
phenotype	NN	phenotype
,	,	,
such	JJ	such
as	IN	as
pathogenic	JJ	pathogenic
canonical	JJ	canonical
splice	NN	splice
site	NN	site
variants	NNS	variant
not	RB	not
covered	VBN	cover
by	IN	by
Sanger	NNP	Sanger
and	CC	and
panel	NN	panel
approaches	NNS	approach
(	-LRB-	(
e.	NNP	e.
g.	NNP	g.
,	,	,
<hi rend="italic">
ADA2	NNP	ADA2
</hi>
:	:	:
c.	NN	c.
-47+2T&gt;C	CD	-47+2t4C
)	-RRB-	)
;	:	;
or	CC	or
large	JJ	large
chromosomal	NN	chromosomal
rearrangements	NNS	rearrangement
,	,	,
encompassing	VBG	encompass
several	JJ	several
genes	NNS	gene
in	IN	in
patients	NNS	patient
with	IN	with
complex	JJ	complex
phenotypes	NNS	phenotype
.	.	.
</s>
<s type="decl">
In	IN	in
those	DT	those
circumstances	NNS	circumstance
,	,	,
an	DT	an
MSM	NNP	MSM
could	MD	could
help	VB	help
find	VB	find
the	DT	the
best	RBS	well
appropriate	JJ	appropriate
strategy	NN	strategy
in	IN	in
accordance	NN	accordance
with	IN	with
the	DT	the
patient	NN	patient
’s	POS	&apos;s
phenotype	NN	phenotype
.	.	.
</s>
</p>
<p>
<s type="decl">
The	DT	the
role	NN	role
of	IN	of
the	DT	the
reference	NN	reference
centers	NNS	center
is	VBZ	be
to	TO	to
determine	VB	determine
whether	IN	whether
or	CC	or
not	RB	not
the	DT	the
clinical/anamnesis/genealogical	JJ	clinical/anamnesis/genealogical
tree	NN	tree
is	VBZ	be
compatible	JJ	compatible
with	IN	with
a	DT	a
known	VBN	know
AID	NN	AID
.	.	.
</s>
<s type="decl">
If	IN	if
compatibility	NN	compatibility
does	VBZ	do
not	RB	not
seem	VB	seem
to	TO	to
be	VB	be
the	DT	the
case	NN	case
,	,	,
the	DT	the
role	NN	role
is	VBZ	be
to	TO	to
evaluate	VB	evaluate
the	DT	the
potential	JJ	potential
added	VBN	add
value	NN	value
to	TO	to
perform	VB	perform
the	DT	the
NGS	NNP	NGS
.	.	.
</s>
<s type="decl">
If	IN	if
this	DT	this
value	NN	value
appears	VBZ	appear
to	TO	to
be	VB	be
low	JJ	low
,	,	,
the	DT	the
reference	NN	reference
center	NN	center
recommends	VBZ	recommend
that	IN	that
no	DT	no
NGS	NNP	NGS
be	VB	be
conducted	VBN	conduct
in	IN	in
discussion	NN	discussion
with	IN	with
geneticists	NNS	geneticist
.	.	.
</s>
<s type="decl">
Thus	RB	thus
,	,	,
this	DT	this
discussion	NN	discussion
decreases	VBZ	decrease
the	DT	the
number	NN	number
of	IN	of
individuals	NNS	individual
whose	WP$	whose
phenotype	NN	phenotype
is	VBZ	be
not	RB	not
typically	RB	typically
enough	RB	enough
.	.	.
</s>
</p>
</text>
